No retraction, correction or concern found when last checked on Nov 1, 2026.

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Anum Glasgow, Jeff Glasgow, Daniel Limonta and 17 more

Proceedings of the National Academy of Sciences · 2020 · CC BY

doi:10.1101/2020.07.31.231746

Abstract

Significance During the ongoing COVID-19 pandemic, protein engineering offers a rapid and powerful approach for building therapeutics to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We use computational design, affinity maturation, and fusion to dimerization domains to engineer “receptor traps” based on wild-type angiotensin-converting enzyme II (ACE2), the target for viral spike-mediated SARS-CoV-2 entry into cells. The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases. ACE2 receptor traps have large binding interfaces and block the entire receptor binding interface, limiting the potential impact of viral escape mutations.

References 61

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome · 2017
No notice
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 · 2020
No notice
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig · 2020
No notice
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays · 2020
No notice
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 · 2020
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
43.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
46.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies · 2020
No notice
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020
No notice
49.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
52.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
53.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
54.
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 · 2020
No notice
55.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
56.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
57.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
58.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
59.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
60.
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2 · 2021
No notice
61.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 5

De novo design of protein structure and function with RFdiffusion · 2023
No notice
Therapeutic antibodies under development for SARS‐CoV‐2 · 2022
Not checked
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 · 2021
No notice
The flexibility of ACE2 in the context of SARS-CoV-2 infection · 2021
No notice
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19 · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.